305:
lab of City of Hope's
Professor Yuman Fong, M.D., to get into tumour cells and start producing CD19. They did this successfully in triple-negative breast, pancreatic, prostate, ovarian, head and neck, and brain cancer cell lines. CF33-CD19 oncolytic virus was then combined with CD19 CAR T cells in vitro and in vivo mice studies. Researchers showed significant activity with mice being cured of their cancer with the CF33-CD19 and CAR T-cell combination, as well as prolonged protective anti-tumour immunity. Solid tumours don't express CD19 on their cell surface, therefore introducing the CF33-CD19 allowed for CD19 to be present on the solid tumour cell surface, as well as helped to reverse the tumour's harsh microenvironment, making it receptive to receiving CAR T-cell therapy.
27:
99:
304:
onCARlytics (CF33-CD19) is a novel immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting utilisation of combination with CD19 targeting agents against solid tumours. Researchers first created an oncolytic virus (CF33-CD19) in the
317:
HER-Vaxx is a B-cell immuno-therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Developed by leading scientists at the
Medical University of Vienna in Austria, the immuno-therapy is constructed from several B-cell
247:
Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially
321:
PD1-Vaxx is a B-cell immuno-therapy which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to
Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range
290:
CEO & Managing
Director Leslie Chong joined the company, initially as COO, in 2015 after working at Genentech in California, USA. HER-Vaxx entered the clinic in 2017, with the company's PD1-Vaxx technology licensed from Ohio State University and the Mayo Clinic the following year. In 2019 the
313:
B-cell immunotherapies link an immunogenic protein with a B-cell epitope and incorporate an adjuvant to produce a B-cell cancer vaccine that induces the body to produce antibodies against the normal self-proteins, such as HER2 or PD-1 (known as breaking immune tolerance). The antibodies produced
282:
cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours. In 2012 a start-up company called
Biolife Science was incorporated to develop this immunotherapy (HER-Vaxx). Early-stage funding was secured from Australian and US investors in 2013, after which
251:
The company's product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours.
337:, an Australian bioentrepreneur based in Sydney who was instrumental in identifying the HER-Vaxx project and taking it public in Imugene. The company's CEO and Managing Director is Leslie Chong, who used to be a Senior Clinical Program Lead at
295:
of City of Hope Cancer Center in
California, USA. In 2021 it also licensed the onCARlytics technology developed by Professor Fong. The company's CHECKvacc (2021) and VAXINIA (2022) technologies have also subsequently entered the clinic.
318:
epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies and in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.
325:
Developed by
Professor Pravin Kaumaya at the Ohio State University in Columbus OH, the immunotherapy is constructed from a single B cell epitope derived from the extracellular domain of PD-1. .
60:
322:
of cancers. PD1-Vaxx has shown great potential in preclinical studies. It outperformed an industry-standard mouse anti-PD-1 antibody in a mouse model of colorectal cancer.
358:
259:(ASX) under the code IMU. In December 2021 it entered the S&P/ASX 200 Index, in effect making it one of the 200 largest companies on the ASX.
46:
78:
256:
121:
314:
following the vaccination are a ‘polyclonal’ mixture of antibodies that bind to different parts of the vaccine antigen.
272:
248:
achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
56:
192:
42:
37:
200:
208:
184:
291:
company then licensed the CF33 oncolytic virus platform, invented by renowned oncologist
Professor
172:
268:
284:
287:
of
Australian drug development company Imugene, whose name was retained after the merger.
334:
166:
352:
135:
115:
26:
292:
125:
338:
98:
279:
276:
153:
267:
Imugene began as a research project in the laboratory of
Professor
275:. Over the nine years from 2004 Wiedermann et al. had developed a
20:
231:
52:
255:
Imugene is a publicly traded company, listed on the
226:
222:
HER-Vaxx; PD1-Vaxx; CHECKvacc; VAXINIA; onCARlytics
218:
160:
149:
141:
131:
113:
105:
181:(Chief Executive Officer & Managing Director)
41:, potentially preventing the article from being
283:Biolife was taken public in December 2013 in a
8:
91:
97:
90:
61:reliable, independent, third-party sources
79:Learn how and when to remove this message
55:by replacing them with more appropriate
359:Cancer organisations based in Australia
38:too closely associated with the subject
7:
14:
333:Imugene's Executive Chairman is
36:may rely excessively on sources
25:
16:Australian biotechnology company
257:Australian Securities Exchange
1:
273:Medical University of Vienna
375:
300:Oncolytic virus technology
96:
213:(Non-Executive Director)
205:(Non-Executive Director)
197:(Non-Executive Director)
189:(Non-Executive Director)
309:B-cell immunotherapies
341:in San Francisco.
93:
173:Executive Chairman
269:Ursula Wiedermann
242:
241:
214:
206:
201:Dr Lesley Russell
198:
190:
182:
176:
89:
88:
81:
366:
285:reverse takeover
238:
235:
233:
212:
209:Dr Jens Eckstein
204:
196:
188:
180:
170:
101:
94:
84:
77:
73:
70:
64:
29:
21:
374:
373:
369:
368:
367:
365:
364:
363:
349:
348:
347:
331:
311:
302:
265:
230:
211:
207:
203:
199:
195:
191:
187:
185:Dr Jakob Dupont
183:
179:
177:
169:
163:
118:
85:
74:
68:
65:
50:
30:
17:
12:
11:
5:
372:
370:
362:
361:
351:
350:
346:
343:
330:
327:
310:
307:
301:
298:
264:
261:
240:
239:
228:
224:
223:
220:
216:
215:
193:Charles Walker
167:Paul A. Hopper
164:
161:
158:
157:
151:
147:
146:
143:
139:
138:
133:
129:
128:
119:
114:
111:
110:
109:Public company
107:
103:
102:
87:
86:
33:
31:
24:
15:
13:
10:
9:
6:
4:
3:
2:
371:
360:
357:
356:
354:
344:
342:
340:
336:
328:
326:
323:
319:
315:
308:
306:
299:
297:
294:
288:
286:
281:
278:
274:
270:
262:
260:
258:
253:
249:
246:
237:
229:
225:
221:
217:
210:
202:
194:
186:
174:
168:
165:
159:
155:
152:
148:
144:
140:
137:
136:Biotechnology
134:
130:
127:
123:
120:
117:
112:
108:
104:
100:
95:
83:
80:
72:
62:
58:
54:
48:
44:
40:
39:
34:This article
32:
28:
23:
22:
19:
332:
324:
320:
316:
312:
303:
289:
266:
254:
250:
244:
243:
178:Leslie Chong
150:Headquarters
106:Company type
75:
69:January 2016
66:
51:Please help
35:
18:
335:Paul Hopper
329:Main people
156:, Australia
92:Imugene Ltd
345:References
293:Yuman Fong
162:Key people
53:improve it
43:verifiable
339:Genentech
116:Traded as
57:citations
353:Category
234:.imugene
219:Products
132:Industry
280:peptide
271:at the
263:History
245:Imugene
227:Website
142:Founded
124::
47:neutral
277:B cell
154:Sydney
236:.com
145:2012
45:and
232:www
126:IMU
122:ASX
59:to
355::
175:)
171:(
82:)
76:(
71:)
67:(
63:.
49:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
